Related Experiment Video
Updated: Aug 5, 2026

10:05
Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
Published on: September 16, 2015
Nucleus accumbens DRD2 receptor agonism attenuates escape behavior
Bridgitte E Côté1, Elaine M Grafelman1, Lisa Moster1
1Department of Biomedical Sciences, Marquette University, Milwaukee, WI, United States.
Frontiers in Neuroscience
|July 28, 2026
Summary
Activating dopamine D2 receptors in the nucleus accumbens disrupts motivated escape behaviors. This suggests that reduced dopamine signaling via D2 receptors may facilitate aversion learning and escape.
Area of Science:
- Neuroscience
- Behavioral Neuroscience
- Molecular Neuroscience
Background:
- The nucleus accumbens (NAc) plays a crucial role in processing rewarding and aversive stimuli, guiding motivated behaviors.
- Dopamine signaling via DRD1 and DRD2 receptors in the NAc is well-studied for reward motivation, but its role in aversion learning is less understood.
- Recent findings challenge traditional views on opposing roles of DRD1 and DRD2 in motivated behavior, highlighting the need to investigate aversion signaling pathways.
Purpose of the Study:
- To investigate the role of dopamine D2 receptor (DRD2) activation within the NAc core in modulating motivated escape behavior.
- To determine if pharmacological activation of DRD2 receptors impairs the ability to escape aversive stimuli.
Main Methods:
- Utilized Sprague Dawley rats (n=21, male and female) for behavioral experiments.
- Administered a DRD2 receptor agonist, quinpirole, directly into the NAc core.
- Assessed escape behavior negatively reinforced by the cessation of aversive white noise.
Main Results:
- Intra-NAc core administration of quinpirole significantly attenuated escape behavior.
- This finding suggests that DRD2 receptor activation interferes with the neural circuits mediating escape from aversive stimuli.
Conclusions:
- The results support the hypothesis that reduced dopamine signaling through DRD2 receptors in the NAc promotes escape behavior.
- This implies that decreased DRD2 signaling may disinhibit aversion-sensitive striatal output pathways, facilitating aversion learning and escape.
- Further characterization of dopamine's role in aversion processing within the NAc is warranted.
Related Concept Videos
Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...

